<< Back To Search

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05257083
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a unique combination of drugs that target the cancer cells in different ways.
  • It aims to enhance the effectiveness of existing therapies by using a multi-drug strategy.
  • Patients will receive the treatment in a controlled environment, allowing for close monitoring of their response.
  • The study includes a diverse group of participants to ensure the findings are applicable to a wide range of patients.
  • Researchers are particularly interested in how this combination therapy can lead to longer remission periods and improved quality of life.
  • Safety and side effects will be closely observed to ensure the treatment is well-tolerated.
Overall, this study is significant because it seeks to provide a more effective treatment option for patients, potentially leading to better management of their condition and improved health outcomes.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: